From the Research
Superdrol (methasterone) is more likely to cause gastrointestinal issues than Halotestin (fluoxymesterone) due to its higher liver toxicity and chemical structure, as evidenced by the most recent study on anabolic androgenic steroid-induced liver injury 1. The liver toxicity associated with Superdrol is a significant concern, as it can lead to severe hepatotoxicity, including cholestatic liver injury, as reported in a study on methasteron-associated cholestatic liver injury 2. This occurs because the liver must process Superdrol extensively, releasing stress signals that affect the digestive system. Additionally, Superdrol's molecular structure makes it more resistant to first-pass metabolism, allowing it to remain active in the system longer and potentially irritate the GI tract directly.
Some key points to consider:
- Superdrol is a 17-alpha alkylated steroid with strong hepatotoxic effects, which can manifest as GI distress, including nausea, appetite loss, and stomach pain.
- The specific chemical configuration of Halotestin results in somewhat different metabolic pathways and typically less severe GI side effects.
- Users of either compound should be aware that both are highly liver toxic, and protective measures such as limiting duration of use, avoiding alcohol, and using liver support supplements like N-acetylcysteine or milk thistle may help reduce, but not eliminate, these adverse effects.
- A study on anabolic androgenic steroid-induced liver injury highlights the importance of considering the potential for liver damage when using these compounds 1.
- Another study on methasteron-associated cholestatic liver injury provides insight into the clinicopathologic findings in cases of hepatotoxicity associated with Superdrol use 2.
It is essential to prioritize the most recent and highest quality study when making a definitive recommendation, and in this case, the study on anabolic androgenic steroid-induced liver injury 1 provides the most up-to-date information on the topic.